A Phase 3 interventional study of LY2189265 and Insulin glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-10-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 22nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 361 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 83rd largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2012, is one of 85 in phase 3, and was the 82nd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).
Rescue therapy (defined as alternative antihyperglycemic medication use or dose modification of oral antihyperglycemic medication [OAM]) may have been initiated during the planned treatment period if the participant discontinued study drug or met prespecified thresholds for severe, persistent hyperglycemia. Efficacy data, as well as data for hypoglycemic episodes from participants who permanently discontinued study treatment but switched to another diabetes medication and remained in the study, were censored from the point of initiating new treatment onwards.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).
Drug: LY2189265 · Drug: Sulfonylureas (SU) · Drug: Biguanide (BG)
Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).
Drug: Insulin glargine · Drug: Sulfonylureas (SU) · Drug: Biguanide (BG)
Also known as: Dulaglutide
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks
Percentage of Participants Who Achieved Glycosylated Hemoglobin (HbA1c) <=6.5% or <7% at 26 Weeks
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a longitudinal logistic regression model with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
Time frame: Up to 26 weeks
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline FBG as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks
Change From Baseline in 8-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks
Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, at bedtime, and before breakfast the next morning (second pre-morning meal). Least squares (LS) means were calculated using analysis of covariance (ANCOVA) model with treatment, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects and baseline SMBG as a covariate.
Time frame: Baseline, Up to 26 weeks
Change From Baseline in Body Weight at 26 Weeks
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline body weight as a covariate, and participant as a random effect.
Time frame: Baseline, 26 weeks
Percentage of Participants With Hypoglycemic Episodes
The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 Weeks
| Milestone | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| Started | 181 | 180 |
| Received at least 1 dose of study drug | 181 | 180 |
| Completed | 173 | 177 |
| Not completed | 8 | 3 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
| percentage of HbA1c | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks | -1.44 ± 0.05 | -0.90 ± 0.05 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a longitudinal logistic regression model with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.
| percentage of participants | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| HbA1c <=6.5% | 51.1 | 24.0 |
| HbA1c <7% | 71.3 | 45.8 |
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline FBG as a covariate, and participant as a random effect.
| milligrams per deciliter (mg/dL) | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks | -34.3 ± 1.9 | -37.8 ± 1.9 |
Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, at bedtime, and before breakfast the next morning (second pre-morning meal). Least squares (LS) means were calculated using analysis of covariance (ANCOVA) model with treatment, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects and baseline SMBG as a covariate.
| milligrams per deciliter (mg/dL) | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| Pre-morning meal (n=178, 179) | -33.49 ± 1.65 | -38.66 ± 1.64 |
| 2 hours post-morning meal (n=178, 179) | -49.54 ± 3.33 | -36.14 ± 3.31 |
| Pre-midday meal (n=178, 179) | -36.16 ± 2.68 | -27.94 ± 2.66 |
| 2 hours post-midday meal (n=178, 179) | -43.51 ± 3.27 | -20.30 ± 3.25 |
| Pre-evening meal (n=178, 179) | -31.14 ± 2.77 | -17.50 ± 2.75 |
| 2 hours post-evening meal (n=177, 178) | -46.68 ± 3.05 | -15.55 ± 3.03 |
| Bedtime (n=177, 172) | -41.53 ± 2.95 | -17.79 ± 2.96 |
| Second pre-morning meal (n=178, 179) | -30.81 ± 1.60 | -37.02 ± 1.59 |
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline body weight as a covariate, and participant as a random effect.
| kilograms (kg) | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| Change From Baseline in Body Weight at 26 Weeks | -0.48 ± 0.17 | 0.94 ± 0.17 |
The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| percentage of participants | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| Percentage of Participants With Hypoglycemic Episodes | 26.0 | 47.8 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2189265 + OAM | — | 9/181 (5%) | 133/181 (73.5%) |
| Insulin Glargine + OAM | — | 3/180 (1.7%) | 111/180 (61.7%) |
| Event | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| Cerebral infarctionNervous system disorders | 2/181 | 0/180 |
| Anal abscessInfections and infestations | 0/181 | 1/180 |
| Spinal cord infarctionNervous system disorders | 0/181 | 1/180 |
| Viith nerve paralysisNervous system disorders | 0/181 | 1/180 |
| Acute myocardial infarctionCardiac disorders | 1/181 | 0/180 |
| CholelithiasisHepatobiliary disorders | 1/181 | 0/180 |
| Hyperplastic cholecystopathyHepatobiliary disorders | 1/181 | 0/180 |
| Urinary tract infectionInfections and infestations | 1/181 | 0/180 |
| FallInjury, poisoning and procedural complications | 1/181 | 0/180 |
| Patella fractureInjury, poisoning and procedural complications | 1/181 | 0/180 |
| Event | LY2189265 + OAM | Insulin Glargine + OAM |
|---|---|---|
| NasopharyngitisInfections and infestations | 49/181 | 46/180 |
| DiarrhoeaGastrointestinal disorders | 22/181 | 4/180 |
| NauseaGastrointestinal disorders | 17/181 | 2/180 |
| ConstipationGastrointestinal disorders | 16/181 | 6/180 |
| VomitingGastrointestinal disorders | 9/181 | 2/180 |
| Lipase increasedInvestigations | 9/181 | 1/180 |
| BronchitisInfections and infestations | 4/181 | 7/180 |
| HypertensionVascular disorders | 6/181 | 6/180 |
| InfluenzaInfections and infestations | 6/181 | 2/180 |
| Back painMusculoskeletal and connective tissue disorders | 5/181 | 5/180 |
All randomized participants who received at least 1 dose of LY2189265 or insulin glargine.
| Age, Continuous(years) | LY2189265 + OAM | Insulin Glargine + OAM | Total |
|---|---|---|---|
| Mean | 57.52 ± 10.48 | 56.14 ± 11.33 | 56.83 ± 10.92 |
| Sex: Female, Male(Participants) | LY2189265 + OAM | Insulin Glargine + OAM | Total |
|---|---|---|---|
| Female | 56 | 47 | 103 |
| Male | 125 | 133 | 258 |
| Race/Ethnicity, Customized(participants) | LY2189265 + OAM | Insulin Glargine + OAM | Total |
|---|---|---|---|
| Asian | 181 | 180 | 361 |
| Region of Enrollment(participants) | LY2189265 + OAM | Insulin Glargine + OAM | Total |
|---|---|---|---|
| Japan | 181 | 180 | 361 |
The record gives a start of Apr 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 3 months after primary completion. A results delay was requested in Sep 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide